Paper Details

  1. Home
  2. Paper Details

Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.

Author: ChaudharyTanushree, FernandezCédric, HauchOle, HeuserMichael, KlibanovOlga M, RivesVincent

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review looked at treatments for acute myeloid leukemia (AML) in people who can't receive standard chemotherapy. The combination of targeted therapies (like venetoclax or ivosidenib) and medications that modify DNA (hypomethylating agents or HMAs) were found to improve survival rates compared to other medications. While side effects were more common with these combinations, the combination of ivosidenib and azacitidine had fewer side effects. Overall, this combination appears to be the most promising treatment for this challenging group of patients.
Paper Details　
Original Abstract of the Article :
<b>Aim:</b> To review clinical evidence for current and emerging treatments for patients with acute myeloid leukemia (AML) who are ineligible for first-line induction chemotherapy. <b>Methods:</b> A systematic literature review was performed (28 October 2021) to identify clinical outcomes including...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2022-1286

データ提供：米国国立医学図書館（NLM）

Acute Myeloid Leukemia: New Hope for Ineligible Patients

This systematic review examines the landscape of treatment options for patients with acute myeloid leukemia (AML) who are ineligible for standard induction chemotherapy. The authors analyzed a significant body of research to assess the efficacy of various treatment approaches, particularly focusing on the combination of targeted therapies with hypomethylating agents. The review highlights the promising results of this combination therapy, particularly in terms of overall survival, event-free survival, and relapse-free survival. The authors acknowledge the presence of side effects with combination therapies, but the benefits appear to outweigh the risks in this difficult-to-treat population.

Targeted Therapy: A Beacon of Hope for AML Patients

This review provides a beacon of hope for patients with AML who are ineligible for standard induction chemotherapy. The study findings suggest that combining targeted therapies with hypomethylating agents can significantly improve outcomes, offering a viable treatment option for this challenging patient population. It's like finding a new path through a desert, offering a chance of survival and hope for those facing a difficult journey.

AML: Navigating Treatment Options with Precision

This review emphasizes the importance of personalized treatment approaches for AML, especially for patients who are ineligible for traditional chemotherapy. The study findings highlight the promise of targeted therapies, offering a more precise and effective approach to treatment. Imagine targeted therapy as a camel caravan equipped with precise navigation tools, allowing it to navigate the complex and challenging terrain of AML with greater accuracy and efficiency.

Dr.Camel's Conclusion

This systematic review offers valuable insights into the treatment landscape for AML patients who are ineligible for standard induction chemotherapy. The research highlights the promise of combining targeted therapies with hypomethylating agents, providing a beacon of hope for this challenging patient population. This research underscores the importance of a personalized approach to cancer treatment, allowing clinicians to navigate the complex terrain of disease with greater precision and efficacy.

Date :
  1. Date Completed 2023-06-02
  2. Date Revised 2023-06-02
Further Info :

Pubmed ID

37170899

DOI: Digital Object Identifier

10.2217/fon-2022-1286

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.